Keywords: Tumors (Post-Treatment), CEST & MT, Glioblastoma, Intranasal, Theranostic
Motivation: Theranostic application of intranasal drug delivery to glioblastoma using multiple CEST contrast.
Goal(s): Our goal is to monitor the drug delivery to brain tumor and evaluate the treatment effect simultaneously.
Approach: We investigated the imaging of liposome-based drug delivery to the brain tumor via intranasal administration,in which the amount of liposome and the tumor response can be detected by CEST MRI at 3T.
Results: CEST contrast at 3.5ppm of tumor region and the tumor size comparison between treatment and control group could indicate the therapeutic effect.CEST contrast at 4.3and-3.5ppm from pre-injection to post-injection in-vivo,could indicate the liposome drug delivery efficacy and drug distribution.
Impact: CEST MRI guided intranasal drug delivery could provide valuable information for assessing efficacy of drug delivery and treatment outcome. This can potentially translate to clinics as a non-invasive theranostic approach for glioblastoma treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords